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Abstract
Background: Considering the scarcity of health care resources and the high costs associated with cardiovascular
diseases, we investigated the spending on cardiovascular primary preventive activities and the prescribing
behaviour of primary preventive cardiovascular medication (PPCM) in Dutch family practices (FPs).
Methods: A mixed methods design was used, which consisted of a questionnaire (n = 80 FPs), video recordings of
hypertension- or cholesterol-related general practitioner visits (n = 56), and the database of Netherlands
Information Network of General Practice (n = 45 FPs; n = 157,137 patients). The questionnaire and video recordings
were used to determine the average frequency and time spent on cardiovascular primary preventive activities per
FP respectively. Taking into account the annual income and full time equivalents of general practitioners, health
care assistants, and practice nurses as well as the practice costs, the total spending on cardiovascular primary
preventive activities in Dutch FPs was calculated. The database of Netherlands Information Network of General
Practice was used to determine the prescribing behaviour in Dutch FPs by conducting multilevel regression
models and adjusting for patient and practice characteristics.
Results: Total expenditure on cardiovascular primary preventive activities in FPs in 2009 was €38.8 million (€2.35
per capita), of which 47% was spent on blood pressure measurements, 26% on cardiovascular risk profiling, and
11% on lifestyle counselling. Fifteen percent (€11 per capita) of all cardiovascular medication prescribed in FPs was
a PPCM. FPs differed greatly on prescription of PPCM (odds ratio of 3.1).
Conclusions: Total costs of cardiovascular primary preventive activities in FPs such as blood pressure
measurements and lifestyle counselling are relatively low compared to the costs of PPCM. There is considerable
heterogeneity in prescribing behaviour of PPCM between FPs. Further research is needed to determine whether
such large differences in prescription rates are justified. Striving for an optimal use of cardiovascular primary
preventive activities might lead to similar health outcomes, but may achieve important cost savings.
Background
Cardiovascular diseases (CVDs) are the leading cause of
death and a major cause of disability and loss of produc-
tivity in adults world wide [1]. The annual cost of CVD is
estimated to be €169 billion a year in the enlarged
European Union and $394 billion (€296) in the USA
[2,3]. CVD is generally caused by a combination of sev-
eral risk factors such as smoking, high blood cholesterol,
high blood pressure, physical inactivity, obesity and over-
weight. Risk factor modification has been unequivocally
shown to reduce mortality and morbidity in people with
or without established CVD [4].
Family practices (FPs) can play an important role in risk
factor modification for people with an increased risk of
CVD. The general practitioner, and the practice nurse and
the health care assistant to some extent, can reduce the risk
of CVD by conducting cardiovascular preventive activities
(cardiovascular primary preventive activities are preventive
activities (e.g. prescribing of blood-pressure-lowering drugs,
or lifestyle counselling) aimed at a determinant of cardio-
vascular disease for people without CVD) [5-9].
As the population ages the annual costs of CVD are
likely to increase. Considering the scarcity of health care
resources and the high costs of CVD [10], a comprehensive
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ities in FPs is crucial for health policy development and
evaluation. However, such an overview of spending on
cardiovascular primary preventive activities in FPs is lack-
ing [11]. Moreover, information is lacking on the propor-
tion of cardiovascular medication prescriptions that are for
primary prevention (i.e., cardiovascular medication aimed
at a determinant of cardiovascular disease for people with
neither cardiovascular nor diabetes or lipid disorders), and
how much general practitioners differ in prescribing beha-
viour regarding primary preventive cardiovascular medica-
tion. Insights into these issues are important as the
amounts spent on cardiovascular medication (predomi-
nantly statins and antihypertensive medication) are consid-
erable [11], but in case of primary prevention may not
always be strictly needed. The Dutch multidisciplinary
guideline for cardiovascular risk management recommends
that people without a history of CVD, diabetes, or lipid dis-
order should receive primary prevention interventions such
as lifestyle recommendations, blood pressure measure-
ments or blood tests if there is a positive family history,
clear overweight, or a patient’sr e q u e s t[ 1 2 ] .T h i sg u i d e l i n e
recommends cardiovascular risk profiling if (i) the systolic
blood pressure (SBP) is 140 mmHg or higher, (ii) the total
cholesterol (TC) is 6.5 mmol/l or higher, or (iii) if the com-
bination age (men ≥ 50 year, women ≥ 55 year) and smok-
ing exists. The decision to prescribe medications for people
without a history of CVD, diabetes or lipid disorders
depends not only on the estimated risk of CVD, the SBP,
and ‘TC/high density lipoprotein cholesterol’-ratio, but also
on patient’s preferences [12].
This study estimates the costs of cardiovascular primary
preventive activities including prescription of primary pre-
ventive cardiovascular medication (PPCM) in FPs in the
Netherlands. This makes it possible to investigate i) what
is done in FPs to prevent CVD in people with increased
risk of CVD, ii) what the total direct medical costs are, iii)
the proportion of cardiovascular medication prescriptions
that are for primary prevention (to separate prevention
from care), and iv) how much FPs differ in prescribing
behaviour of PPCM.
Methods
We used a mixed methods design, which consisted of
three parts: i) a questionnaire among family practices
(FPs); ii) video recordings of hypertension-, cholesterol-
and/or endocrine-related general practitioner visits; and
iii) the database of Netherlands Information Network of
General Practice. There was an overlap in the FPs used
for the three different approaches.
Questionnaire
Literature [12,13] and interviews with general practi-
tioners (n = 3) were used to determine cardiovascular
primary preventive activities for patients without CVD.
Six activities were selected for the questionnaire: 1)
blood pressure measurement; 2) cardiovascular risk pro-
filing; 3) a blood test related activity (i.e., explaining the
need for a blood test to the patient, filling out a request
for a blood test, and/or sharing the blood test results
with the patient); 4) family history; 5) lifestyle history;
and 6) lifestyle counselling. The questionnaire com-
prised questions on practice size and location, and
about the frequency of the above mentioned cardiovas-
cular primary preventive activities per week provided by
general practitioners, health care assistants and practice
nurses.
The questionnaire was emailed to 80 FPs from the
‘Netherlands Information Network of General Practice’
(LINH-DB) [14,15] in 2009. Each year LINH contains 80
FPs and is a representative network of Dutch FPs as it
takes into account the representativeness regarding prac-
tice type, urbanisation and the software system that is
used [16]. The sample of practices originates from the mid
1990’s; eighty FPs are sufficient to make disease-related
conclusions at the Dutch national level. Practices partici-
pate on a voluntary basis. The LINH database holds longi-
tudinal data on morbidity, prescribing, and referrals, based
on the routine electronic patient records that are kept by
the participating practices. In order to enable longitudinal
analyses, changes in the set of participating practices are
kept to a minimum. There is a waiting list for practices to
participate in the network. When a practice quits partici-
pating in the network, a new practice is invited. These FPs
are spread throughout the Netherlands and are represen-
tative of all Dutch FPs. Reminders were sent to non-
respondents two and four weeks later.
Video recordings
We used video recorded general practitioner consultations
which were recorded as part of a larger study into doctor-
patient communication in general practice in 2007-2008
[17]. Neither general practitioners nor patients were aware
of the topics of interest for the researchers. Forty Dutch
general practitioners participated in the study. These gen-
eral practitioners are representative of Dutch general prac-
titioners regarding age, practice form and number of days
worked [17]. Eight hundred and eight consultations were
video-recorded. These consultations were randomly
recorded on week days, and are expected to represent
Dutch general practice consultations. The study protocol
adheres to the Dutch privacy legislation, approved by the
Dutch Data Protection Authority. However, approval by a
medical ethics committee was not required for this obser-
vational study, because the study did not interfere with a
GPs usual work process and patients were not confronted
with whatever project-related intervention. Our research
complied with the Helsinki Declaration. All participating
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consent form before the recording of the consultation.
We included all recorded hypertension-, cholesterol-
and endocrine-related visits for further analyses (we
assumed that, for example, the time spent on a blood pres-
sure measurement did not differ between primary and sec-
ondary prevention). The time spent on any of the six
cardiovascular preventive activities (see previous para-
graph) was measured.
Database of Netherlands Information Network of General
Practice
Data on diagnosis and prescriptions were derived from the
‘Netherlands Information Network of General Practice’
(LINH-DB) [14,15]. Focusing on the period 2005-2007,
data from 161 FPs, spread throughout the Netherlands,
were collected (data on the periods 2008 and 2009 were
not yet available at the time of study). To investigate the
prescription of primary preventive cardiovascular medica-
tion (PPCM) in FPs, we included FPs with complete data
sets over the whole period 2005-2007. PPCM is defined as
cardiovascular medication (i.e., all kind of beta blockers
and statins) aimed at a determinant of cardiovascular dis-
ease for people without cardiovascular diseases, diabetes
(types 1 and 2), or disorders of lipid metabolism (e.g.
hypercholesterolemia). Cardiovascular treatment of
patients who had consulted their general practitioner for
cardiovascular diseases, diabetes, or lipid disorders in
2005-2007 was not regarded of primary preventive nature.
Patients with these conditions were excluded, because the
focus of the manuscript is on primary prevention. Primary
prevention focuses on patients without cardiovascular dis-
eases and/or diabetes and/or disorders of lipid metabolism,
because in that case - according the Dutch guidelines - the
use of measures belongs to regular care.
Data analysis
Based on the questionnaire, we determined the average
weekly frequency a FP carried out the different cardiovas-
cular primary preventive activities. The averages were
determined separately for the general practitioners, health
care assistants, and practice nurses in each practice. The
video recorded consultations were used to determine the
average amount of time required to carry out each of
these activities. Based on these two figures we determined
the average amount of time spent carrying out cardiovas-
cular primary prevention activities per week. This was
extrapolated to an annual figure. Finally, we estimated the
total direct costs of cardiovascular primary preventive
activities in FPs in the Netherlands in 2009 by taking into
account the annual income and full time equivalents of
general practitioners, health care assistants, and practice
nurses as well as practice costs (i.e. housing, medical
equipment, insurance and transportation) [18-20].
The volume of prescriptions of PPCM in FPs was
determined using data of FPs with complete data sets
from the period 2005 through 2007. Second, to get
insight into which part of prescription of cardiovascular
medication was intended as preventive, the patients
were divided into four patient groups: 1) patients with
cardiovascular and diabetes (types 1 and 2) and/or dis-
orders of lipid metabolism (e.g. hypercholesterolemia);
2) patients with cardiovascular disease, but without dia-
betes or lipid disorders; 3) patients without cardiovascu-
lar disease, but with diabetes or lipid disorders; and 4)
patients with neither cardiovascular disease nor diabetes
or lipid disorders (primary prevention). The proportion
of patients with i) prescription of cardiovascular medica-
tion, and ii) prescription of PPCM were calculated based
on the existence of CVD, diabetes or lipid disordersas
previously outlined. Multilevel analyses were conducted
to investigate whether differences in prescription of car-
diovascular medication for each patient group could be
explained by family practice characteristics (urbanisation
and practice type) and/or by patients’ characteristics
(age, gender, living in a disadvantaged neighbourhood
(i.e. a geographically localised community within a larger
city, town or suburb that contained a large proportion
of people with a low social economic status), and insur-
ance type). This was achieved using a mixed effects
regression model, which estimates ‘fixed’ coefficients b
for covariates at the patient level and at the family prac-
tice level i in FP j (Xij)a n d‘random’ coefficients for the
FPs j (θj). The parameter θj is assumed to be normally
distributed with mean μ and variance τ
2:
Logit (P(Yij =1 |Xij)) = βXij + θjwith ∼ N( μ, τ2).
The variance (τ
2) estimated in the model is a measure
of the between family practice differences, and indicates
the spreading of the prescribing behaviour of the indivi-
dual FPs. To facilitate interpretation of the estimated
between-FPs differences, we compared the FPs at the
higher end of the outcome distribution (the 90
th percen-
tile) with the FPs at the lower end (the 10
th percentile)
of the outcome distribution. The relative difference in
odds of prescribing behaviour in these two groups of
FPs can be calculated from the parameter τ
2:8 0 %O R
range = exp (2.58*τ). The value 2.58 is the z-value corre-
sponding to the width of the 80% (i.e. from the 10
th per-
centile to the 90
th percentile) confidence interval in a
normal distribution (2*1.29).
Results
Frequency of primary preventive activities
The response rate of FPs for the questionnaire was 85%
(68/80). The average frequency of each identified cardio-
vascular primary preventive activity in FPs varied
according to the activity and the discipline (Figure 1).
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reported activity: 16.7, 13.1, and 10.5 times per week for
a general practitioner, a practice nurse, and a health
care assistant respectively. General practitioners, practice
nurses, and health care assistants were involved in each
of the six cardiovascular primary preventive activities.
Time spent on primary preventive activities
Seven percent (n = 56) of the 808 video-recorded con-
sultations were hypertension-, cholesterol- and endo-
crine-related. There were on average 1.7 hypertension-,
cholesterol- and endocrine-related visits per general
practitioner (SD 1.0; range 1-4). Cardiovascular risk pro-
filing had the longest mean duration, whereas the
family/lifestyle history had the shortest mean duration
(244 and 24 seconds respectively) (Table 1). Additional
File 1: Appendix shows the time spent in minutes per
week per discipline on primary preventive activities in
family practice to prevent cardiovascular diseases
(appendix 1).
Costs
Total expenditure on cardiovascular primary preventive
activities in FPs was €38.8 million or €2.35 per capita in
the Netherlands in 2009, of which 39.8% were practice
costs (€15.4 million) and 60.2% were personnel costs
(€23.3 million) (Table 2). The vast majority of the per-
sonnel costs were made by general practitioners (€18.6
million; 79.8%). Forty-seven percent (€1.11 per capita) of
the total expenditure was related to blood pressure mea-
surements, 26% to cardiovascular risk profiling (€0.60
per capita), and 11% to lifestyle counselling (€0.25 per
capita). Approximately €181 million (i.e. 15% of the
total costs of cardiovascular medication [21]) or €11 per
capita was spent on PPCM (see next paragraph for
more details).
Prescription of cardiovascular medication in FPs
Forty-five out of 161 FPs (28%; n = 157,137 patients)
from the ‘Netherlands Information Network of General
Practice’ had complete data sets over the whole period
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Figure 1 Frequency of primary preventive activities in family practice to prevent cardiovascular diseases in the Netherlands in 2009,
in amount per week per discipline.
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prescription of cardiovascular medication differed
greatly between FPs for all four patient groups (Table
3). On average 19.2% (30,275/157,137) of the patients of
the FPs had a prescription for cardiovascular medica-
tion; the prescription rate for cardiovascular medication
varied between 12.0% and 27.0% for the FP with the
lowest and highest prescription rates, respectively. Fif-
teen percent (4,543/30,275) of all cardiovascular medica-
tion prescribed in FPs was a PPCM.
The results of the multilevel analyses showed that the
difference between FPs in prescription of cardiovascular
medication for each patient group was partly explained
by family practice and patient characteristics. In other
words, for each patient group the value of τ
2 decreased
when practice and/or patient characteristics were taken
into account (Table 4). However, although adjusted for
practice and patient characteristics, the odds range indi-
cates considerable variation in prescribing behaviour
between practices. Focusing on the patients ‘without
cardiovascular, diabetes and lipid disorders’ (i.e. patient
group 4), the between practice differences in outcome
were 3.1 fold. Hence, although adjusted for practice and
patient characteristics, the odds on PPCM in practices
at the higher end of the outcome distribution (odds =
1.75; Table 4) was 3.1 times higher than in practices at
the lower end (odds = 0.57; Table 4). Adjusted for prac-
tice and patient characteristics, 10 out of 45 FPs (22.2%)
had a significantly lower prescription rate of PPCM, and
15 out of 45 FPs (33%) had a significantly higher pre-
scription rate compared to the average prescription rate
of all FPs. The coefficients of the random effects logistic
regression model indicated that the probability of receiv-
ing a prescription for a cardiovascular medication for
patient group 4 was significantly higher for older
patients and for females, and lower for patients with pri-
vate insurance and for duo FPs (Table 5). The urbaniza-
tion level of the FP as well as the neighbourhood of the
patient did not significantly influence the PPCM pre-
scribing behaviour.
Discussion
This study gave a comprehensive overview of spending
on cardiovascular primary preventive activities in FPs,
which is quite innovative and crucial for health policy
development and evaluation. Additionally, this study
contributed to the literature on the variation on cardio-
vascular medication prescriptions; especially on primary
preventive cardiovascular medication (PPCM). We
found that in family practices (FPs) €38.8 million or
€2.35 per capita was spent on cardiovascular primary
preventive activities such as taking a family and lifestyle
history, cardiovascular risk profiling, blood pressure
measurement, blood test related activity, and lifestyle
counselling in the Netherlands in 2009. General practi-
tioners, health care assistants, and practice nurses were
all involved in these primary preventive activities, from
which blood pressure measurement was the most fre-
quently conducted cardiovascular primary preventive
activity. Nineteen percent of the patients of FPs had a
prescription for cardiovascular medication. Fifteen per-
cent of these prescriptions (approximately €181 million
or €11 per capita at a national level) were primarily a
preventive one. Family practices differed considerably
with respect to prescription rates of primary preventive
cardiovascular medication (PPCM).
Table 2 Estimated national spending in family practices to prevent cardiovascular diseases in the Netherlands in 2009
Personnel costs Practice costs Total costs Costs per Portion total
GP HCA PN patient costs
(€)( €)( €)( €)( €)( €) (%)
Family history 777,496 87,028 35,761 719,706 1,619,991 0.10 4.2
Lifestyle history 772,581 101,909 49,509 685,751 1,609,749 0.10 4.2
Cardiovascular risk profiling 4,780,739 870,361 374,741 3,935,307 9,961,147 0.60 25.7
Blood pressure measurement 8,747,392 1,636,260 530,036 7,312,378 18,226,067 1.11 47.0
Blood test related activity 1,532,813 544,058 76,046 1,040,853 3,193,769 0.19 8.2
Lifestyle counselling 1,988,230 246,905 167, 852 1,739,688 4,142,675 0.25 10.7
Total 18,599,251 3,486,520 1,233,945 15,433,683 38,753,399 2.35 100.0
GP = general practitioner; HCA = health care assistant; PN = practice nurse.
Table 1 Duration of primary preventive activities in
family practice to prevent cardiovascular diseases in
seconds (based on n = 56 video-taped general practice
visits in 2007/2008)
Duration
Mean (SD)
Family history 23.7 (13.8)
Lifestyle history 24.1 (21.7)
Cardiovascular risk profiling 244.0 (172.5)
Blood pressure measurement 105.7 (54.8)
Blood test related activity 71.1 (22.2)
Lifestyle counselling 46.1 (47.1)
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dies on the costs of cardiovascular primary preventive
activities in FPs to compare our outcomes with. Further-
more, there are no previous studies establishing the
volume of prescription of PPCM in family practices. How-
ever, in a CVD prevention context, Pelletier-Fleury et al.
(2007) showed that there was a high between-doctor varia-
bility of CVD prevention in FPs [22]. This is in line with
our study, which showed that there was a substantial
difference in prescription of preventive cardiovascular
medication between FPs. We could compare the propor-
tion of patients with a prescription of a CVD medication,
based on our data, with the proportion of patients with a
prescription of a CVD medication based on the Drug
Information System of the Health Care Insurance Board
(GIP; http://www.gipdatabank.nl/). According to the GIP
Table 3 Prescription of cardiovascular medication in family practices in the Netherlands in 2007 (n = 45 family
practices; n = 157,137 patients)
in 2005-2007 Prescription cardiovascular medication in 2007
Patient group**(n) Cardio-vascular disease Diabetes or lipid disorders Lowest*
(%)
Highest*
(%)
Median
(%)
Mean
(%; n)
1 (9,954) Yes Yes 75.5 95.6 87.2 87.3 (8,685)
2 (20,976) Yes No 49.5 77.2 65.2 64.4 (13,720)
3 (9,287) No Yes 15.8 56.1 36.0 36.3 (3,327)
4 (116,920) No No 1.0 9.3 3.5 3.9 (4,543)
Total (157,137) 12.0 27.0 19.4 19.2 (30,275)
Notes:
* lowest = family practice with the lowest prescription rate; highest = family practice with the highest prescription rate.
** patient group 1 = patients with cardiovascular and diabetes (types 1 and 2) and/or disorders of lipid metabolism (e.g. hypercholesterolemia); patient group 2
= patients with cardiovascular disease, but without diabetes or lipid disorders; patient group 3 = patients without cardiovascular disease, but with diabetes or
lipid disorders; and patient group 4 = patients with neither cardiovascular nor diabetes or lipid disorders (primary prevention).
Table 4 Differences in prescribing behaviour of cardiovascular medication between family practices (n = 45; n =
157,137 patients) with unadjusted random effect estimates, adjusted random effects estimates for family practice
characteristics (i.e. urbanization and practice type), random effects estimates for patient characteristics (i.e. age,
gender, social economic status and insurance type), and adjusted for practice characteristics and patient
characteristics
τ
2 OR range
Patients with CVD and endocrine diseases (n = 9,954)
Unadjusted 0.15 0.61 - 1.65
Adjusted for FP characteristics only 0.13 0.63 - 1.59
Adjusted for patient characteristics only 0.14 0.62 - 1.62
Adjusted for FP and patient characteristics 0.12 0.64 - 1.56
Patients with CVD (n = 20,976)
Unadjusted 0.6 0.73 - 1.36
Adjusted for FP characteristics only 0.5 0.76 - 1.32
Adjusted for patient characteristics only 0.5 0.75 - 1.33
Adjusted for FP and patient characteristics 0.4 0.77 - 1.29
Patients with endocrine diseases (n = 9,287)
Unadjusted 0.13 0.63 - 1.58
Adjusted for FP characteristics only 0.11 0.65 - 1.53
Adjusted for patient characteristics only 0.10 0.67 - 1.50
Adjusted for FP and patient characteristics 0.08 0.69 - 1.44
Patients without CVD and endocrine diseases (n = 116,920)
Unadjusted 0.29 0.50 - 2.00
Adjusted for FP characteristics only 0.25 0.52 - 1.91
Adjusted for patient characteristics only 0.23 0.54 - 1.86
Adjusted for FP and patient characteristics 0.19 0.57 - 1.75
Notes: 1) OR = odds ratio; the OR range is calculated as the range between exp(-1.29*τ) and exp(1.29*τ);
2) FP = family practice; 3) The variance τ
2 estimated in the random effects model is a measure of the between-FPs differences, and indicated the spreading of
prescribing behaviour of the individual FPs; 4) CVD = cardiovascular disease.
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tion in 2007. This was quite similar to our study results,
which showed that 19.2% of the patients had CVD medi-
cation. This suggests that the practices in our study were
largely representative for all practices in the Netherlands.
The substantial differences in prescription of PPCM in
FPs can partly be explained by the various combinations
of patient characteristics per FP as the appropriateness of
prescribing should be based on absolute cardiovascular
risk. However, prescribing behaviour may also play a role
in the explanation of these substantial differences. Differ-
ences in recording behaviour probably play a small role in
the explanation of the variation in prescription of PPCM
between FPs, because a better or worse recording beha-
viour will influence the numerator and denominator in a
similar way.
For all four patient groups there is a considerable
unexplained variation that justifies further research to
investigate why these differences exist, and perhaps
more importantly to get insight into the impact of dif-
ferences in prescribing behaviour on CVD morbidity
and mortality for these four patient groups. Positive (i.e.
high prescribing behaviour of cardiovascular medication
results in higher survival rates and less adverse effects)
as well as negative (no difference in health outcomes
between FPs with a high or a low prescribing behaviour
of cardiovascular medication) outcomes are relevant. A
positive outcome justifies the expenditure on cardiovas-
cular medication from a societal perspective. A negative
outcome indicates that important cost savings may be
achieved by reassessing the prescription of cardiovascu-
lar medication, because a relatively low prescribing
behaviour of cardiovascular medication may achieve
similar health outcomes compared with a relatively high
prescribing behaviour. For the same reason, further
research is recommended to investigate whether higher
spending on cardiovascular preventive activities reduces
prescribing and vice a versa.
Differences in PPCM prescribing behaviour between
FPs that is not explained by patient’s or practice’sc h a r -
acteristics may indicate under-treatment. From a
patient-care perspective it is important to have insight
into these differences. Under-treatment justifies an
increase in resources, whereas over-treatment indicates
inefficiency. Another relevant implication for clinical
practice is that our research shows that the current
guideline is interpreted differently. Improvement of the
current guideline may be useful, especially for primary
prevention, for which the discrepancy between family
practices is considerable.
Our study has some limitations. First, although we
identified primary preventive activities for patients with
unrecognized cardiovascular disease from literature and
interviews with general practitioners, this careful proce-
dure does not guarantee that activities we did not include
are irrelevant. Second, we assumed that data from the
questionnaire reliably indicated the true extent of pri-
mary preventive activities. By definition, data taken from
self-administered questionnaires are estimations. How-
ever, the FPs who filled in the questionnaire belong to
the Netherlands Information Network of General Prac-
tice, were representative for all Dutch FPs, and had
experience with filling in self-complete questionnaires.
Therefore, we believe that the estimates based on the
questionnaire are not that far from reality. Third, we
assumed that all patients with a history of CVD should
have contacted their general practitioner at least once for
cardiovascular reasons in 2005-2007. As a result some
Table 5 Influence of patient and family practice characteristics on primary preventive cardiovascular prescribing
behaviour (n = 45 family practices; n = 116,920 patients)
Random effect Adjusted SE p-value
Patient
characteristics
Age (per 10 year) 0.512 0.009 < 0.001
Gender (female vs male) 0.191 0.032 < 0.001
Type of insurance (private vs national) -0.158 0.035 < 0.001
Disadvantage neighbourhood (yes vs no) 0.140 0.088 0.11
FP characteristics Practice type (ref. single handed)
Duo -0.540 0.214 0.01
Group -0.127 0.184 0.49
Health care center -0.133 0.255 0.60
Urbanisation (ref. very strongly)
Strongly 0.249 0.237 0.29
Moderately -0.126 0.221 0.57
Weakly 0.001 0.219 0.99
not 0.226 0.193 0.24
Note: Values are random effect logistic regression coefficients. A positive number means a higher probability on prescription of cardiovascular medication.
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general practitioner for cardiovascular reasons in 2005-
2007 were regarded as primary preventive nature. As this
latter group is small, we do not expect that the reported
results are changed considerably. Fourth, although we
took into account different factors that might have an
impact on variations in prescribing (e.g., age, gender,
neighbourhood), there may be other factors for which we
did not account for such as ethnicity and marital status.
Fifth, we defined expenditure on medication as those
spent on statins and beta blockers. However, other (pri-
mary) preventive cardiovascular medication exists.
Aspirin, for example, can be used as a (primary) preven-
tive cardiovascular medication as well. However, this
medication is also used as an analgesic to relieve minor
aches and pains, as an antipyretic to reduce fever, and as
an anti-inflammatory medication. Therefore for practical
reasons we focused on statins and beta blockers only.
The costs of total spending on primary preventive cardio-
vascular medication may therefore be an underestima-
tion. Sixth, to investigate the prescription of primary
preventive cardiovascular medication in FPs, we had to
include FPs with complete data sets over the whole per-
iod 2005-2007. From the FPs with complete data sets, the
FPs’ characteristics (practice type, urbanisation) were
quite similar to the Dutch national situation of FPs.
N e v e r t h e l e s s ,w ec a n n o tr u l eo u tt h a tF P sw i t hi n c o m -
plete data sets may have different prescribing behaviour
than FPs with incomplete data sets. Finally, our results
may have been influenced by specific characteristics of
the Dutch health care system, in which the family prac-
tice plays a pivotal role. Having said this, we still think
our study has a wider applicability because medical pro-
cedures used for the prevention and treatment of cardio-
vascular diseases in the Netherlands are very similar to
those in other developed countries.
Conclusions
This study provides important new insights regarding the
costs of cardiovascular primary preventive activities,
which is crucial for health policy development and eva-
luation. Although the frequency of cardiovascular pri-
mary preventive activities such as blood pressure
measurements and lifestyle counselling in FPs are size-
able, total costs of these activities are relatively low com-
pared to the costs of primary preventive cardiovascular
medication (PPCM) prescribed by general practitioners.
Further research is needed to determine whether these
relatively high costs of PPCM are justified as there is a
considerable heterogeneity in prescribing behaviour of
PPCM between FPs. Striving for an optimal use of cardi-
ovascular primary preventive activities might lead to
similar health outcomes, but may achieve important cost
savings.
Additional material
Additional File 1: Appendix. Time spent on primary preventive
activities in family practice to prevent cardiovascular diseases in the
Netherlands in 2009, in minutes per week per discipline.
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